Sullivan Mark sold $514K of DFTX

Sullivan Mark (Chief Legal Officer) sold 14,051 shares of Definium Therapeutics, Inc. (DFTX) at $36.57 ($0.51M total) on 2026-09-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sullivan Mark
Published Sep 30, 2026, 1:10 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 1:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$DFTX
Bearish
medium confidence
Mentioned
$DFTX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DFTXBearishLow
01

Why it matters

Provides fresh, primary data on insider activity, useful for short-term sentiment assessment.

02

Market read

Insider sale may cause slight short-term price pressure; limited broader market relevance.

03

What to watch

Potential upcoming clinical data or financing events could offset sell pressure.

Relevance 4/10Novelty 5/10Timing: post-market today

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$DFTXBearishMedium confidence
Context

Chief Legal Officer sold 14,051 shares for $513,845 via a 10b5-1 plan, reducing his stake.

Expected impact

likely downward pressure as market prices in the insider sell

Evidence & confidence

C-level insider sale of over $500k, though modest, can be interpreted as a bearish signal.

Market effects

Minimal impact on biotech sector; isolated insider transaction.

Negligible effect on broader market.

None

Counterpoint

The sale may be routine liquidity, not a bearish indicator.

Key entities

  • Definium Therapeutics, Inc.

    Biotech firm listed under ticker DFTX.

  • Sullivan Mark

    Chief Legal Officer of Definium Therapeutics.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$DFTXHighAI 8/10

Definium Therapeutics Eyes FDA Filing for LSD Treatment After Three Positive Phase 3 Studies

Definium Therapeutics (DFTX) reported positive results from early studies of its LSD treatment for autism, showing consistent effects in participants. The company plans to file for FDA approval after completing Phase 3 studies. Definium is also addressing safety concerns and plans to study individuals with more profound impairments. The company's lead products include MM120 and DT402, currently in clinical trials for various disorders.

$DFTXMedAI 8/10

Definium (DFTX) Q3 2026 Earnings Call Transcript

Definium (DFTX) reported Q3 2026 earnings, highlighting FDA breakthrough therapy designations for DT120. The company plans an NDA filing in H1 2027 and shared positive clinical data for DT120 and DT402. DT120 showed significant improvements in anxiety and depression trials, with plans to expand into PTSD. DT402 showed early promise in autism spectrum disorder studies. The company is preparing for a potential launch, focusing on commercial infrastructure and provider engagement.

$DFTXMed

What Definium Therapeutics (DFTX) Said on Its Q3 Earnings Call

Definium Therapeutics (DFTX) reported Q3 earnings, highlighting progress in clinical trials for DT120 and DT402. DT120 showed tolerability in Phase 3 studies, with top-line results for Ascend expected in 2027. DT402's early autism study was halted after five participants showed consistent efficacy signals. R&D expenses rose to $46.1M, with a net loss of $51M, narrower than the previous year. The company plans commercial preparations for DT120, targeting a pricing range of $30,000-$75,000.

$DFTXHighAI 8/10

Why is Definium Therapeutics stock gaining today?

Definium Therapeutics (DFTX) shares rose 0.2% after reporting Q3 2026 results. The company narrowed its net loss to $50.96M, reported positive Phase 3 results for DT120 ODT in anxiety, and received FDA Breakthrough Therapy Designation for depression. Cash reserves increased to $1.05B. Analysts maintain a Buy consensus with raised price targets.

$DFTXHigh

Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent

Definium Therapeutics, Inc. (DFTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights Reported positive topline Phase 3 results from two Phase 3 studies of DT120 ODT in generalized anxiety disorder (GAD) Received FDA Breakthrough Therapy Designation for DT120 ODT